MX2009013384A - Formulacion de liberacion extendida, y metodo para tratar disregulacion adrenergica. - Google Patents
Formulacion de liberacion extendida, y metodo para tratar disregulacion adrenergica.Info
- Publication number
- MX2009013384A MX2009013384A MX2009013384A MX2009013384A MX2009013384A MX 2009013384 A MX2009013384 A MX 2009013384A MX 2009013384 A MX2009013384 A MX 2009013384A MX 2009013384 A MX2009013384 A MX 2009013384A MX 2009013384 A MX2009013384 A MX 2009013384A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- release formulation
- extended release
- agonist
- treating
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 230000001800 adrenalinergic effect Effects 0.000 title abstract 2
- 230000008482 dysregulation Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000013265 extended release Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 230000036470 plasma concentration Effects 0.000 abstract 2
- 150000008051 alkyl sulfates Chemical class 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe una composición y método para tratar disregulación adrenérgica administrando la composición, en donde la composición comprende un agonista de receptor a2-adrenérgico; una matriz hidrofílica farmacéuticamente aceptable y un retardador de liberación de un alquilsulfato de metal; en las modalidades, la composición provee una liberación sostenida del agonista, en donde después de la administración de la composición, no más de una vez aproximadamente cada 12 horas a un sujeto que tiene una concentración en plasma en estado estable del agonista de receptor a2- adrenérgico, la relación de máximo a mínimo de la concentración del agonista en plasma es no mayor de aproximadamente 1.9.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94293407P | 2007-06-08 | 2007-06-08 | |
PCT/US2008/066036 WO2008154339A2 (en) | 2007-06-08 | 2008-06-06 | Extended release formulation and method of treating adrenergic dysregulation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009013384A true MX2009013384A (es) | 2010-01-25 |
Family
ID=39869944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009013384A MX2009013384A (es) | 2007-06-08 | 2008-06-06 | Formulacion de liberacion extendida, y metodo para tratar disregulacion adrenergica. |
Country Status (8)
Country | Link |
---|---|
US (4) | US20090087490A1 (es) |
EP (1) | EP2155170A2 (es) |
JP (1) | JP2010529142A (es) |
KR (1) | KR20100020459A (es) |
AU (1) | AU2008261957A1 (es) |
CA (1) | CA2689978A1 (es) |
MX (1) | MX2009013384A (es) |
WO (1) | WO2008154339A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090087490A1 (en) * | 2007-06-08 | 2009-04-02 | Addrenex Pharmaceuticals, Inc. | Extended release formulation and method of treating adrenergic dysregulation |
US20100172991A1 (en) * | 2007-06-08 | 2010-07-08 | Henry Joseph Horacek | Extended Release Formulation and Methods of Treating Adrenergic Dysregulation |
EP2309993A1 (en) * | 2008-06-25 | 2011-04-20 | US Worldmeds LLC | Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery |
US8623409B1 (en) | 2010-10-20 | 2014-01-07 | Tris Pharma Inc. | Clonidine formulation |
KR101446066B1 (ko) * | 2012-12-14 | 2014-10-01 | 박재돈 | 구안파신 함유 경구용 서방성 캡슐제 조성물 |
WO2020106330A1 (en) * | 2018-07-18 | 2020-05-28 | Pillsy, Inc. | Smart drug delivery and monitoring device, kit, and method of use for pill compounds |
US11918689B1 (en) | 2020-07-28 | 2024-03-05 | Tris Pharma Inc | Liquid clonidine extended release composition |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3065143A (en) * | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
US3236857A (en) * | 1961-10-09 | 1966-02-22 | Boehringer Sohn Ingelheim | 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products |
US3427378A (en) * | 1965-02-12 | 1969-02-11 | American Cyanamid Co | Sustained release encapsulated formula |
US3590117A (en) * | 1969-03-24 | 1971-06-29 | Richardson Merrell Inc | Long-lasting troche containing guar gum |
US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
US4094964A (en) * | 1977-05-10 | 1978-06-13 | Hoffmann-La Roche Inc. | Clonidine assay |
US4201211A (en) * | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
DD146547A5 (de) * | 1978-07-15 | 1981-02-18 | Boehringer Sohn Ingelheim | Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen |
US4279928A (en) * | 1979-04-02 | 1981-07-21 | William H. Rorer, Inc. | Method of lowering blood pressure |
US4312878A (en) * | 1979-04-27 | 1982-01-26 | Boehringer Ingelheim International Gmbh | Method of eliminating opiate withdrawal symptoms with clonidine in humans |
US4226849A (en) * | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
US4357469A (en) * | 1979-06-14 | 1982-11-02 | Forest Laboratories, Inc. | Carrier base material for prolonged release therapeutic compositions |
US4291015A (en) * | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
FR2470599A1 (fr) * | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
US4312879A (en) * | 1980-08-14 | 1982-01-26 | Richardson-Merrell Inc. | Clonidine and lofexidine as antidiarrheal agents |
US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4994260A (en) * | 1982-05-28 | 1991-02-19 | Astra Lakemedel Aktiebolag | Pharmaceutical mixture |
US4556678A (en) * | 1982-06-24 | 1985-12-03 | Key Pharmaceuticals, Inc. | Sustained release propranolol tablet |
IL70071A (en) | 1982-11-01 | 1987-12-31 | Merrell Dow Pharma | Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient |
FR2535202B1 (fr) | 1982-11-03 | 1985-08-09 | Fabre Sa Pierre | Comprimes de theophylline a liberation controlee et leur procede de fabrication |
US4680186A (en) * | 1983-03-07 | 1987-07-14 | Granite State Packing Company, Inc. | Portion controlled sliced fresh whole muscle meat product |
US4612008A (en) * | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US5082668A (en) * | 1983-05-11 | 1992-01-21 | Alza Corporation | Controlled-release system with constant pushing source |
US4571333A (en) * | 1983-06-14 | 1986-02-18 | Syntex (U.S.A.) Inc. | Controlled release naproxen and naproxen sodium tablets |
US4505890A (en) * | 1983-06-30 | 1985-03-19 | E. R. Squibb & Sons, Inc. | Controlled release formulation and method |
US5002776A (en) * | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
US4894240A (en) * | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
US4795327A (en) * | 1984-03-26 | 1989-01-03 | Forest Laboratories, Inc. | Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants |
US4540566A (en) * | 1984-04-02 | 1985-09-10 | Forest Laboratories, Inc. | Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose |
US4851228A (en) * | 1984-06-20 | 1989-07-25 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic |
US4603141A (en) * | 1984-11-30 | 1986-07-29 | Giles Thomas D | Oral clonidine treatment of congestive heart failure |
US4587257A (en) * | 1984-12-14 | 1986-05-06 | Alcon Laboratories, Inc. | Control of ocular bleeding using clonidine derivatives |
US4685918A (en) * | 1985-02-01 | 1987-08-11 | Merck & Co., Inc. | Lipid osmotic pump |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
US4785014A (en) * | 1985-06-07 | 1988-11-15 | Yale University | Use of clonidine in memory enhancement |
US4883649A (en) * | 1985-09-10 | 1989-11-28 | The University Of Michigan | Iodinated clonidine derivatives as radioactive imaging tracers |
US4734285A (en) * | 1985-10-28 | 1988-03-29 | The Dow Chemical Company | Sustained release compositions |
US4946848A (en) * | 1985-10-29 | 1990-08-07 | Baker Cumins Dermatologicals, Inc. | Method of treating pruritus with nalmefene and clonidine |
EP0243891B1 (en) * | 1986-04-29 | 1991-08-14 | Hoechst-Roussel Pharmaceuticals Incorporated | A laminar structure for administering a chemical at a controlled release rate |
US4798725A (en) * | 1986-06-16 | 1989-01-17 | Norwich Eaton Pharmaceuticals, Inc. | Sustained release capsule |
US5212196A (en) * | 1986-10-21 | 1993-05-18 | Alcon Laboratories, Inc. | Control of post-surgical intraocular pressure using clonidine derivatives |
US4981696A (en) * | 1986-12-22 | 1991-01-01 | E. I. Du Pont De Nemours And Company | Polylactide compositions |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US4874613A (en) * | 1987-03-06 | 1989-10-17 | Baker Cummins Pharmaceuticals, Inc. | Taste concealing pharmaceutical dosage unit |
US4786503A (en) * | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
US4880632A (en) * | 1987-09-08 | 1989-11-14 | The United States Of America | Prevention of fescue toxicosis |
IL87710A (en) * | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
US4902515A (en) * | 1988-04-28 | 1990-02-20 | E. I. Dupont De Nemours And Company | Polylactide compositions |
US5175052A (en) * | 1988-05-11 | 1992-12-29 | Nitto Denko Corporation | Adhesive tape preparation of clonidine |
US5178868A (en) * | 1988-10-26 | 1993-01-12 | Kabi Pharmacia Aktiebolaq | Dosage form |
US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
US5230896A (en) * | 1989-10-12 | 1993-07-27 | Warner-Lambert Company | Transdermal nicotine delivery system |
IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
US5212162A (en) * | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
US5209746A (en) * | 1992-02-18 | 1993-05-11 | Alza Corporation | Osmotically driven delivery devices with pulsatile effect |
US5221278A (en) * | 1992-03-12 | 1993-06-22 | Alza Corporation | Osmotically driven delivery device with expandable orifice for pulsatile delivery effect |
AU707843B2 (en) * | 1993-10-13 | 1999-07-22 | Concordia Pharmaceuticals Inc. | Extended release clonidine formulation |
US5484607A (en) * | 1993-10-13 | 1996-01-16 | Horacek; H. Joseph | Extended release clonidine formulation |
US5372255A (en) * | 1993-12-29 | 1994-12-13 | Lever Brothers Company, Division Of Conopco, Inc. | Packing shroud |
US5419917A (en) * | 1994-02-14 | 1995-05-30 | Andrx Pharmaceuticals, Inc. | Controlled release hydrogel formulation |
CA2205553C (en) | 1994-12-16 | 2009-04-07 | Warner-Lambert Company | Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process |
US6245350B1 (en) * | 1994-12-16 | 2001-06-12 | Warner-Lambert Company | Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process |
FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
IT1298575B1 (it) | 1998-02-06 | 2000-01-12 | Vectorpharma Int | Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di |
PE20001396A1 (es) * | 1999-01-18 | 2000-12-23 | Gruenenthal Chemie | Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista |
SI1169024T1 (sl) * | 1999-03-31 | 2006-06-30 | Janssen Pharmaceutica Nv | Predzelatinirani skrob v formulaciji s kontroliranim sproscanjem |
US6500459B1 (en) * | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
JP4359412B2 (ja) * | 1999-09-28 | 2009-11-04 | パナセア バイオテック リミテッド | ニメスリドを含む制御放出組成物 |
DE60038536T2 (de) * | 1999-09-30 | 2009-06-10 | Penwest Pharmaceuticals Co. | Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe |
US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
EP2347756B1 (en) * | 2001-07-06 | 2019-05-08 | Veloxis Pharmaceuticals A/S | Controlled agglomeration |
US6811794B2 (en) * | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
FR2834212B1 (fr) * | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
US6726931B2 (en) * | 2002-04-08 | 2004-04-27 | Standard Chem. & Pharm. Co., Ltd. | Process for preparing oral sustained-release formulation of felodipine |
ZA200204331B (en) | 2002-05-30 | 2003-03-26 | Jb Chemicals & Pharmaceuticals | Pharmaceutical composition for controlled drug delivery system. |
MY136318A (en) * | 2002-07-25 | 2008-09-30 | Pharmacia Corp | Sustained-release tablet composition |
US20050051922A1 (en) * | 2002-09-20 | 2005-03-10 | Avinash Nangia | Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same |
EP1581230A2 (en) * | 2002-12-04 | 2005-10-05 | Nascime Limited | Method and compositions for treating anxiety |
EP1663216B1 (en) * | 2003-08-29 | 2011-11-02 | Veloxis Pharmaceuticals A/S | Modified release compositions comprising tacrolimus |
US8987322B2 (en) * | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
PT1897558E (pt) * | 2005-06-09 | 2013-11-06 | Norgine Bv | Preparação sólida de 2-hexadeciloxi-6-metil-4h-3,1- benzoxazin-4-ona |
PL2457563T3 (pl) * | 2006-05-09 | 2017-09-29 | Mallinckrodt Llc | Stałe postacie dawkowania o zmodyfikowanym uwalnianiu rzędu zerowego |
WO2008079868A1 (en) * | 2006-12-22 | 2008-07-03 | Drugtech Corporation | Clonidine composition and method of use |
CN101588794A (zh) | 2007-01-25 | 2009-11-25 | 万能药生物有限公司 | 调节释放药物组合物及其制备方法 |
US20090087490A1 (en) * | 2007-06-08 | 2009-04-02 | Addrenex Pharmaceuticals, Inc. | Extended release formulation and method of treating adrenergic dysregulation |
-
2008
- 2008-06-06 US US12/134,444 patent/US20090087490A1/en not_active Abandoned
- 2008-06-06 EP EP08770274A patent/EP2155170A2/en not_active Withdrawn
- 2008-06-06 CA CA2689978A patent/CA2689978A1/en not_active Abandoned
- 2008-06-06 WO PCT/US2008/066036 patent/WO2008154339A2/en active Application Filing
- 2008-06-06 KR KR1020097025277A patent/KR20100020459A/ko not_active Application Discontinuation
- 2008-06-06 JP JP2010511351A patent/JP2010529142A/ja active Pending
- 2008-06-06 AU AU2008261957A patent/AU2008261957A1/en not_active Abandoned
- 2008-06-06 MX MX2009013384A patent/MX2009013384A/es active IP Right Grant
-
2009
- 2009-09-16 US US12/560,648 patent/US20100209510A1/en not_active Abandoned
- 2009-11-10 US US12/615,477 patent/US7884122B2/en not_active Expired - Fee Related
-
2011
- 2011-04-08 US US13/082,724 patent/US20110245314A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2008261957A1 (en) | 2008-12-18 |
US20110245314A1 (en) | 2011-10-06 |
WO2008154339A2 (en) | 2008-12-18 |
US20090087490A1 (en) | 2009-04-02 |
CA2689978A1 (en) | 2008-12-18 |
WO2008154339A3 (en) | 2009-07-30 |
US7884122B2 (en) | 2011-02-08 |
US20100063123A1 (en) | 2010-03-11 |
US20100209510A1 (en) | 2010-08-19 |
EP2155170A2 (en) | 2010-02-24 |
WO2008154339A9 (en) | 2009-10-01 |
KR20100020459A (ko) | 2010-02-22 |
JP2010529142A (ja) | 2010-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009013384A (es) | Formulacion de liberacion extendida, y metodo para tratar disregulacion adrenergica. | |
HK1125291A1 (en) | Method of using guava extract and composition including guava extract | |
NZ610701A (en) | Once daily formulation of lacosamide | |
BRPI0412314A (pt) | derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina | |
NZ599847A (en) | Pharmaceutical composition comprising a glp-1 agonist and methionine | |
BRPI0514474A (pt) | multiparticulados | |
ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
AR070731A1 (es) | Composicion farmaceutica para farmacos poco solubles | |
WO2013022783A3 (en) | Progesterone containing oral dosage forms and related methods | |
NZ599594A (en) | Fast dissolving solid dosage form | |
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
WO2006113631A3 (en) | Bioenhanced compositions | |
RU2009120990A (ru) | Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции | |
RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
NZ589469A (en) | Niacin and NSAID combination for reducing niacin-induced flushing | |
RS20080430A (en) | Antibiotic compositions of modified release and process of production thereof | |
MX2011013648A (es) | Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos. | |
EA200800370A1 (ru) | Новая фармацевтическая лекарственная форма ингибитора фермента циклооксигеназы с модифицированным высвобождением | |
WO2009034431A3 (en) | Controlled-release dosage forms for varenicline | |
MX2009006319A (es) | Derivados de 5-[4-(azetidin-3-iloxi)-fenil] -2-fenil-5h tiazolo [5,4-c] piridin-4-ona y su uso como antagonistas del receptor de mch. | |
PE20081106A1 (es) | Comprimidos pediatricos de capecitabina | |
MX2010009395A (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos. | |
BR0307278A (pt) | Formulação oral de liberação imediata, e, método para preparar uma formulação | |
MX2009002228A (es) | Composiciones y metodos para tratar o prevenir glaucoma o el avance del mismo. | |
JP2010529142A5 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights |